Incidence and risk factors of intraprocedural hypoxia during bedside intravitreal ranibizumab injection for retinopathy of prematurity: a multicenter retrospective study
This multicenter retrospective study of 74 premature infants in Saudi Arabia found that bedside intravitreal ranibizumab injection for retinopathy of prematurity is associated with a low incidence (16.2%) of transient, non-severe hypoxia, with lower birth weight and gestational age identified as significant risk factors.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Every year, thousands of babies are born too soon, their bodies still developing the complex systems needed to survive outside the womb. Among the most delicate challenges these premature infants face is a condition called retinopathy of prematurity, a disorder where the blood vessels in the eyes fail to grow correctly. If left untreated, this can lead to blindness. For decades, the standard way to fix this was to use a laser to burn away the undeveloped parts of the retina, a procedure that stops the disease but also permanently removes part of the eye's peripheral vision. In recent years, doctors have increasingly turned to a gentler alternative: injecting a tiny amount of medicine directly into the eye to help the blood vessels grow normally. This medicine, known as ranibizumab, has become a trusted tool, but because it is given to fragile newborns who are often still in the intensive care unit, doctors needed to know exactly how these tiny patients handle the stress of the procedure itself.
The core question was not whether the medicine worked, but whether the act of giving it caused the babies to struggle to breathe. When a doctor performs an injection on a newborn, even with just numbing drops and no heavy sedation, the baby must lie still while their eyelids are held open and a needle enters the eye. This moment of stress can sometimes cause a baby's heart rate to slow or their oxygen levels to drop. In a large, multi-hospital study conducted across the Al Qassim region of Saudi Arabia, researchers set out to measure exactly how often this happens and to find out which babies are most at risk. They looked back at the records of 74 premature infants who received this injection between 2020 and 2026, watching their oxygen levels continuously from the moment the procedure started until thirty minutes after it ended.
The study found that while the procedure is generally safe, it is not entirely without risk for the smallest patients. Out of the 74 babies treated, 12 experienced a temporary drop in oxygen levels during or shortly after the injection. Most of these drops were mild, meaning the oxygen level fell just a little bit, and two babies had a moderate drop. Crucially, no baby experienced a severe drop in oxygen that would have been life-threatening, and only a handful of the infants needed any extra medical help to recover. The researchers discovered that the risk was not random; it was closely tied to how small and how early the baby was born. The babies who had the most trouble were those born with the lowest birth weights and the shortest time spent in the womb. In fact, the lower a baby's birth weight was, the more likely they were to have a drop in oxygen, with birth weight emerging as the single strongest predictor of this reaction.
Interestingly, the study also looked at other factors that doctors often worry about, such as how long a baby had been on oxygen therapy before the procedure, the mother's health during pregnancy, or whether the baby was part of a twin pregnancy. The data showed that these factors did not independently cause the oxygen drops. While babies who had been on oxygen for a longer time did seem to have more trouble in the initial analysis, this was likely because those babies were also smaller and less developed to begin with. Once the researchers accounted for the baby's size and age, the length of oxygen therapy was no longer a separate cause of the problem. This distinction is vital because it tells doctors that the physical size and maturity of the infant are the true indicators of risk, rather than the history of their respiratory support.
The results offer a clear path forward for medical teams caring for these vulnerable children. The study confirms that giving this eye medicine at the bedside is a safe option for the vast majority of premature infants, with the disease successfully clearing up in over 80 percent of the cases. However, the findings emphasize that the smallest babies, particularly those with extremely low birth weights, require the most careful attention. By keeping a close watch on their oxygen levels throughout the entire process, doctors can catch any temporary dips immediately and ensure the baby recovers without harm. This approach allows the most fragile infants to receive a treatment that saves their sight while keeping their breathing stable, balancing the need for a cure with the reality of their delicate physiology.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.